Article
Akt as a target for cancer therapy: more is not always better (lessons from studies in mice)
30 May 2017
Abstract excerpt
The PI3K/Akt signalling pathway is one of the most frequently altered signalling networks in human cancers and has become an attractive target in anticancer therapy. Several drugs targeting this pathway are currently in different phases of clinical trials. However, accumulating reports suggest that adverse effects such as hyperglycaemia and hyperinsulinaemia accompany treatment with pan-PI3K and pan-Akt...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
